Rusan unveils APOSAN® 3ml Multi-Dose Pen

VMPL
Mumbai (Maharashtra) [India], March 31: Rusan Healthcare Pvt. Ltd., the marketing and distribution arm of Rusan Pharma Limited, an integrated global pharmaceutical company, has announced the launch of the multi-dose delivery pen device - APOSAN® 3ml Pen (Apomorphine Hydrochloride solution for injection in cartridge)(10mg/ml)(3ml pre-filled cartridges) for treatment of motor fluctuations commonly known as 'ON-OFF' episodes in patients suffering from Parkinson's disease (PD).
In 2018, Rusan was the first company in India to launch APOSAN® Apomorphine Hydrochloride solution for injection (10mg/ml) (2ml and 5ml ampoules). Since APOSAN®'s launch in India, Rusan has observed remarkable clinical impact and consistently positive patient experiences, underscoring Apomorphine's value as a transformative option in Parkinson's management.
The company now offers the complete range of Apomorphine Hydrochloride in different fill volumes namely - 2ml injection, 3ml in pre-filled cartridge with a 'Multi-dose PEN device' and 5ml for continuous 'Infusion PUMPS' to meet distinct clinical scenarios in PD management, such as rapid rescue from OFF episodes using PEN devices and sustained symptom control using infusion PUMPS.

PD is estimated to affect nearly 10 to 11.7 million people globally, with India accounting for a significant and growing share of the patient population. However, the clinical perception is shifting: Early-Onset Parkinson's Disease (EOPD), defined as diagnosis after the age of 20 years and before 50 years, now represents a growing share of the global burden, with incidence and prevalence tripling between 1990 and 2021, as reported in the Journal of Neurology, Neurosurgery & Psychiatry 2026. This clearly indicates that Parkinson's is not confined to older adults, and the changing age profile emphasises the importance of increased awareness, early diagnosis and coverage, to ensure that Parkinson's care remains accessible across India
The APOSAN® 3ml PEN offers a multi-dose, dial-a-dose mechanism with an enhanced dose-visibility window, thereby enabling accurate and consistent dose administration. The APOSAN® 3ml PEN reduces handling complexity, and supports safer, more reliable self-administration reducing the risk of dosing errors. The APOSAN® 3ml PEN device's lightweight, portable design enables convenient, dependable subcutaneous administration at home, empowering patients to manage their therapy promptly.
Commenting on the launch, Ms Malavika Kaura Saxena, Chief Marketing Officer, Rusan Healthcare, stated, "The APOSAN® 3 ml PEN is a major step forward, offering a portable, multi-use system for reliable apomorphine delivery. Complementing this innovation, the APOSAN® HOPE Program provides structured onboarding, guided support, and patient-centric services that make advanced rescue therapy easier to adopt and sustain. By simplifying training, coordination, and day-to-day therapy management, the APOSAN® HOPE Program helps patients and families use the therapy with confidence and continuity."
Also, commenting on the launch, Dr. Kunal Saxena, Managing Director, Rusan Pharma Limited, stated, "The launch of APOSAN® 3ml Pen reflects Rusan's focused commitment to advancing Parkinson's care through accessible and scalable treatment solutions. A defining strength of the brand is Rusan's fully integrated manufacturing model. By producing the API internally at its USFDA & EU GMP accredited facility, the company upholds rigorous quality governance, reduces reliance on external suppliers, and secures a consistent, high-integrity supply chain for this critical therapeutic product. Through innovations like APOSAN® 3ml PEN, we aim to empower patients and caregivers while continuing to expand access to advanced Parkinson's care across India."
ABOUT APOSAN® HOPE PROGRAM
APOSAN®'s advanced delivery ecosystem is supported by the APOSAN® HOPE Program. Managed by Rusan Healthcare, the initiative is designed to equip healthcare professionals, patients, and caregivers with the training and resources needed to optimise treatment outcomes for managing OFF episodes. https://aposanhopeprogram.com/
ABOUT RUSAN HEALTHCARE
Rusan Healthcare (RHC) Pvt. Ltd., is the dedicated marketing and distribution arm of Rusan Pharma Limited in India. It focuses on bringing forward innovative treatments and specialises in the area of Pain management, treatment of Addiction, Parkinson's management and critical care. As the customer-facing entity, RHC bridges the gap between pharmaceutical manufacturing and patient accessibility and availability across India. By combining the manufacturing excellence of Rusan Pharma, RHC is committed to expanding the reach of specialised therapies through innovative technologies such as transdermal patches, long-acting injectable formulations with a robust distribution network, making it accessible to patients across India.
(ADVERTORIAL DISCLAIMER: The above press release has been provided by VMPL. ANI will not be responsible in any way for the content of the same.)